AIDS-related non-Hodgkin's lymphoma: etiology, epidemiology, and impact of highly active antiretroviral therapy.
Lymphoproliferative disorders (LPD) occur more frequently in the immunosuppressed host compared to those who are immunocompetent. The biological and clinical characteristics of a particular LPD are specific to the underlying immune defect, though there are clear similarities in the various tumor types that occur. Immunosuppression-related LPD are more frequently associated with gamma-herpesviruses suggesting that the immunologic environment influences tumorigenesis. Clinical outcomes may be optimized when appropriate treatment strategies are based on consideration of the underlying immunodeficiency and on the tumor biology. Consistent with this observation, in AIDS-related lymphomas (ARL), tumor biology, clinical presentations, and treatment outcomes are correlated with the CD4 cell count. This review will consider the role of immune deficiency in HIV disease on ARL pathogenesis and epidemiology, and the impact that highly active antiretroviral therapy has had in this disease.
Little
Richard F
RF
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bldg 10, Room 10S255, 9000 Rockville Pike, Bethesda, MD 20892-1868, USA. rlittle@helix.nih.gov
D023241:Antiretroviral Therapy, Highly Active; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D011379:Prognosis; D016896:Treatment Outcome